Opinion|Videos|November 12, 2025

Applying Third-Line Therapy in mCRC: Community vs Academic Settings

Panelists discuss how community and academic settings differ in applying third-line therapies for metastatic colorectal cancer and how collaboration benefits patients.

Panelists describe clinical scenarios where patients may receive third-line therapy in community vs academic settings, noting differences in resources, expertise, and support.

Community practices may offer more accessibility and continuity of care, whereas academic centers may be better suited for complex cases or clinical trial enrollment.

They emphasize the importance of collaboration between settings to ensure equitable and consistent care for patients, regardless of treatment location.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo